Regeneron Pharmaceuticals, Inc.

Overview

• Regeneron is a fully integrated biotechnology company that invents, develops, manufactures and commercializes medicines for people with serious diseases.
• Product and candidate programs address eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological disorders, hematologic conditions, infectious diseases and rare diseases.
• Core strategy: maintain a foundation in scientific research and drug development using proprietary technologies, and combine clinical development, manufacturing and commercial capabilities to operate as an integrated, multi-product biotechnology company.

Financial highlights (selected)

| Year | Revenues (USD millions) | Net income (USD millions) | Net income per share — diluted (USD) | |------|--------------------------:|---------------------------:|--------------------------------------:| | 2025 | 14,342.9 | 4,504.9 | 41.48 | | 2024 | 14,202.0 | 4,412.6 | 38.34 | | 2023 | 13,117.2 | 3,953.6 | 34.77 |

Selected products and net product sales (USD millions)

EYLEA family

EYLEA HD (aflibercept 8 mg) | Year | U.S. | ROW | Total | |------:|-----:|----:|------:| | 2025 | 1,636.9 | 932.7 | 2,569.6 | | 2024 | 1,201.1 | 239.9 | 1,441.0 | | 2023 | 165.8 | 0.0 | 165.8 |

EYLEA (aflibercept) | Year | U.S. | ROW | Total | |------:|-----:|----:|------:| | 2025 | 2,747.8 | 2,573.6 | 5,321.4 | | 2024 | 4,767.1 | 3,336.9 | 8,104.0 | | 2023 | 5,719.6 | 3,495.2 | 9,214.8 |

Combined EYLEA HD and EYLEA | Year | U.S. | ROW | Total | |------:|-----:|----:|------:| | 2025 | 4,384.7 | 3,506.3 | 7,891.0 | | 2024 | 5,968.2 | 3,576.8 | 9,545.0 | | 2023 | 5,885.4 | 3,495.2 | 9,380.6 |

Dupixent (dupilumab)

| Year | U.S. | ROW | Total | |------:|-----:|----:|------:| | 2025 | 13,187.0 | 4,619.7 | 17,806.7 | | 2024 | 10,398.7 | 3,749.3 | 14,148.0 | | 2023 | 8,855.6 | 2,732.5 | 11,588.1 |

Libtayo (cemiplimab)

| Year | U.S. | ROW | Total | |------:|-----:|----:|------:| | 2025 | 944.7 | 507.5 | 1,452.2 | | 2024 | 787.3 | 429.5 | 1,216.8 | | 2023 | 538.8 | 330.0 | 868.8 |

Praluent (alirocumab)

| Year | U.S. | ROW | Total | |------:|-----:|----:|------:| | 2025 | 262.5 | 594.3 | 856.8 | | 2024 | 241.7 | 523.3 | 765.0 | | 2023 | 182.4 | 456.5 | 638.9 |

Kevzara (sarilumab)

| Year | U.S. | ROW | Total | |------:|-----:|----:|------:| | 2025 | 371.4 | 203.2 | 574.6 | | 2024 | 270.2 | 188.5 | 458.7 | | 2023 | 214.7 | 171.2 | 385.9 |

Other products and indications

• Evkeeza (evinacumab)
• Ordspono (odronextamab) — follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL)
• Lynozyfic (linvoseltamab) — relapsed/refractory multiple myeloma
• Inmazeb (atoltivimab, maftivimab, odesivimab) — treatment for infection caused by Zaire ebolavirus
• Veopoz (pozelimab) — CHAPLE (CD55-deficient protein-losing enteropathy)
• ARCALYST (rilonacept) — CAPS, FCAS, MWS, DIRA, recurrent pericarditis
• ZALTRAP (ziv-aflibercept) — metastatic colorectal cancer

Product sales and collaborations

• Regeneron records net product sales of EYLEA HD and EYLEA in the United States. Bayer records net product sales outside the United States. Regeneron records its share of profits from outside the United States as collaboration revenue.
• Selected collaboration/territory arrangements:
  • EYLEA HD and EYLEA outside the U.S.: Bayer
  • Dupixent and Kevzara: collaboration with Sanofi
  • Praluent: Regeneron responsible for U.S. development and commercialization; Sanofi responsible outside the U.S.
  • Evkeeza: Regeneron handles U.S.; Ultragenyx handles outside the U.S.
  • ARCALYST: Kiniksa responsible for development and commercialization
  • ZALTRAP: Sanofi responsible for development and commercialization

Business model and risks

• A portion of the business depends on collaborations, licenses and third-party manufacturers. Those relationships expose the company to regulatory, pricing and reimbursement risks that could affect financial results.
• The company’s Form 10-K contains forward-looking statements and risk factors.